VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Oct. 16, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that a new preclinical study demonstrates the potential of the Company’s proprietary compounds to partially repair brain damage that results from a key marker of pathology seen in Alzheimer’s disease and other types of neurodegeneration.
